Can cannabis light (CBD) improve the quality of life for Parkinson's patients?

Over the past 10 years there has been a significant increase in the popularity and consumption of cannabis, both for recreational and therapeutic purposes. More and more research is confirming the therapeutic properties of Cannabis and its active chemical compounds. Among the latter we find cannabidiol, with the abbreviation CBD. This cannabinoid has potential medical applications, including that for treating symptoms related to Parkinson's disease.

CANNABIDIOLO (CBD)

CBD is one of the hundred active cannabinoids present in Cannabis and represents 40% of the plant extract of this plant. One of the main reasons why CBD is now being researched in the medical field is that, unlike the more popular THC (the "recreational" component), it is not psychoactive. Put simply, CBD doesn't bust. This is a very important aspect in clinical therapies, where we always try to minimize side effects. According to numerous studies, even at high dosages, CBD is well tolerated by our body and, therefore, safe for human consumption. Some of the most important therapeutic properties of CBD are the reduction of nausea, anxiety, depression, the contrast of the development of cancer and cancer cells and other important properties found in the scientific literature. Unfortunately, most of these clinical trials come from animal testing, while exhaustive research has not yet been conducted on humans. Furthermore, CBD remains illegal in many parts of the world, a further reason why this field of research should be investigated and the effects on human health and potentially treatable pathologies verified.

CBD AND PARKINSON'S DISEASE

According to several studies conducted in Brazil, Israel, Czechoslovakia, Spain and Italy (indicated below) by independent teams, cannabidiol treatment can improve the quality of life of Parkinson's patients. Some animal studies also confirm that cannabis compounds have the ability to slow the progression of Parkinson's disease and other neurodegenerative diseases.

 

OFFICIAL PUBLICATIONS

September 2004
"Survey on Cannabis use in Parkinson's disease: Subjective improvement of motor symptoms"

Edited by: Charles University in Prague

Sample: 339 patients

Result: "An anonymous questionnaire sent to all patients attending the Prague Movement Disorder Center revealed that 25% of 339 respondents had taken cannabis and 45.9% of these described some form of benefit."

July 2005
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. "

Edited by: Departamento de Bioquímica y Biología Molecular III, Facultad de Medicina, Universidad Complutense, 28040-Madrid, Spain

Result: “Our results support the view of a potential neuroprotective action of cannabinoids against in vivo and in vitro 6-hydroxydopamine toxicity, which may be relevant for PD. Our data indicate that these neuroprotective effects could be due, among other things, to the antioxidant properties of some cannabinoids of plant origin, or exerted through the ability of cannabinoid agonists to modulate glial function, or a combination of both mechanisms. "

PUBMED full text filed: http://www.sciencedirect.com/science/article/pii/S0969996104002827

November 2009
"Cannabidiol for the treatment of psychosis in Parkinson's disease."

Edited by: Department of Neuropsychiatry and Medical Psychology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. awzuardi@fmrp.usp.br

Sample: 6 patients

Result: "These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD."

Full text deposited SAGE Journals : http://journals.sagepub.com/doi/abs/10.1177/0269881108096519

December 2009
"Cannabidiol : a promising drug for neurodegenerative disorders?"

A care of : Department of Experimental Pharmacology, Faculty of Pharmacy, University of Naples Federico II, Via D. Montesano 49, Naples, Italy. iuvone@unina.it

The result : "However, among Cannabis compounds, cannabidiol (CBD), which lacks any unintended psychotropic effects, can represent a very promising agent with the highest perspective for therapeutic use."

Full text deposited PUBMED : http://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2008.00065.x/full

March 2014
"Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson's disease : an open-label observational study."

By the care of : Department of Neurology, Rabin Medical Center, Beilinson Hospital, Petach Tikva ; and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. < < <

Sample : 22 patients

Risuted : " There was also significant improvement of sleep and pain scores. No significant adverse effects of the drug were observed. The study says that cannabis might have a place in the therapeutic armamentarium of PD. Larger, controlled studies are needed to verify the results. "

November 2014
"Effects of cannabidiol in the treatment of patients with Parkinson's disease : an exploratory double-blind trial."

In the care of :
1) Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil INCT Translational Medicine (CNPq), São Paulo, Brazil Barretos School of Health Sciences-Dr. Paulo Prata, Barretos, Brazil mchagas@fmrp.usp.br mchagas@facisb.edu.br.
2) Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil INCT Translational Medicine (CNPq), São Paulo, Brazil.
3Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
4) Laboratório Interdisciplinar de Investigação Médica, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Sample : 140 patients

The result : "Our mitigation point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities ; however, studies with larger samples and specific objectives are required before definitive evidence can be drawn."

December 2015
"The neuroprotection of cannabidiol against MPPmetabolism -induced toxicity in PC12 cells aggression trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease."

In the care of :
1) Department of Clinical Analyses, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil. Electronic address : neife@fcfrp.usp.br.
2) Department of Clinical Analyses, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.

The result : "Our findings suggest that CBD has a neurorestorative potential independent of NGF that might contribute to its neuroprotection against MPP (+), a neurotoxin relevant to Parkinson's disease."

Full text deposited PUBMED : http://www.sciencedirect.com/science/article/pii/S0887233315300047

 

Source http://comitatoparkinson.it/

English